SG11202101910QA - Method for high throughput peptide-mhc affinity screening for tcr ligands by stabilised, peptide-free mhc complexes - Google Patents
Method for high throughput peptide-mhc affinity screening for tcr ligands by stabilised, peptide-free mhc complexesInfo
- Publication number
- SG11202101910QA SG11202101910QA SG11202101910QA SG11202101910QA SG11202101910QA SG 11202101910Q A SG11202101910Q A SG 11202101910QA SG 11202101910Q A SG11202101910Q A SG 11202101910QA SG 11202101910Q A SG11202101910Q A SG 11202101910QA SG 11202101910Q A SG11202101910Q A SG 11202101910QA
- Authority
- SG
- Singapore
- Prior art keywords
- peptide
- mhc
- stabilised
- high throughput
- affinity screening
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6818—Sequencing of polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862731337P | 2018-09-14 | 2018-09-14 | |
DE102018122546.6A DE102018122546B3 (en) | 2018-09-14 | 2018-09-14 | High-throughput peptide MHC affinity screening method for TCR ligands |
US201962873102P | 2019-07-11 | 2019-07-11 | |
PCT/EP2019/074511 WO2020053398A2 (en) | 2018-09-14 | 2019-09-13 | Method for high throughput peptide-mhc affinity screening for tcr ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101910QA true SG11202101910QA (en) | 2021-04-29 |
Family
ID=68576566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101910QA SG11202101910QA (en) | 2018-09-14 | 2019-09-13 | Method for high throughput peptide-mhc affinity screening for tcr ligands by stabilised, peptide-free mhc complexes |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200088726A1 (en) |
EP (1) | EP3850363A2 (en) |
KR (1) | KR20210060530A (en) |
CN (1) | CN113195529A (en) |
AU (1) | AU2019338666A1 (en) |
BR (1) | BR112021004734A2 (en) |
CA (1) | CA3112401A1 (en) |
CR (1) | CR20210177A (en) |
DE (1) | DE102018122546B3 (en) |
PE (1) | PE20210746A1 (en) |
SG (1) | SG11202101910QA (en) |
TW (1) | TW202017940A (en) |
WO (1) | WO2020053398A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022502045A (en) * | 2018-09-28 | 2022-01-11 | ダンマークス テクニスケ ウニヴェルシテート | High-throughput epitope identification and T cell receptor specificity determination using loadable detection molecules |
US20210048442A1 (en) * | 2019-08-13 | 2021-02-18 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:mhc binding polypeptides |
MX2022010461A (en) | 2020-02-24 | 2022-12-13 | Immatics Us Inc | Methods for expanding t cells for the treatment of cancer and related malignancies. |
WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
JP2024502034A (en) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス,アイエヌシー. | CD8 polypeptides, compositions, and methods of using them |
DE102021100038A1 (en) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | MODIFIED CD8 POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF |
DE102021109811B3 (en) | 2021-04-19 | 2022-09-22 | Biocopy Gmbh | Process for the production of complex arrays |
WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
WO2023066932A1 (en) | 2021-10-18 | 2023-04-27 | Immatics Biotechnologies Gmbh | Stabilized mhc molecules |
WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10225139A1 (en) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Methods for the identification of immunoreactive peptides |
GB2398300A (en) * | 2003-02-17 | 2004-08-18 | Isis Innovation | Method and compositions for boosting immune response |
JP2007519910A (en) | 2004-01-28 | 2007-07-19 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Methods for identifying and quantifying tumor-related peptides |
US8992937B2 (en) | 2006-08-28 | 2015-03-31 | Washington University | Disulfide trap MHC class I molecules and uses therefor |
EP2167536A1 (en) * | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
GB201002730D0 (en) | 2010-02-18 | 2010-04-07 | Uni I Oslo | Product |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
DE112011100879A5 (en) * | 2011-08-30 | 2013-11-14 | Jacobs University Bremen Ggmbh | Gene codes for an MHC class I molecule, plasmid, expression system, protein, multimer, reagent and kit for analyzing a T-cell frequency |
ES2700984T3 (en) * | 2012-12-21 | 2019-02-20 | Hoffmann La Roche | Multifunctional proteins comprising MHC class I multivalent disulfide-linked |
GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
US11129872B2 (en) | 2016-08-11 | 2021-09-28 | Kite Pharma, Inc. | Methods of making and using soluble MHC molecules |
US11851471B2 (en) * | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
-
2018
- 2018-09-14 DE DE102018122546.6A patent/DE102018122546B3/en active Active
-
2019
- 2019-09-12 TW TW108132986A patent/TW202017940A/en unknown
- 2019-09-13 US US16/569,691 patent/US20200088726A1/en active Pending
- 2019-09-13 EP EP19769767.5A patent/EP3850363A2/en active Pending
- 2019-09-13 CN CN201980059543.1A patent/CN113195529A/en active Pending
- 2019-09-13 SG SG11202101910QA patent/SG11202101910QA/en unknown
- 2019-09-13 KR KR1020217010873A patent/KR20210060530A/en not_active Application Discontinuation
- 2019-09-13 AU AU2019338666A patent/AU2019338666A1/en active Pending
- 2019-09-13 PE PE2021000317A patent/PE20210746A1/en unknown
- 2019-09-13 CR CR20210177A patent/CR20210177A/en unknown
- 2019-09-13 BR BR112021004734-4A patent/BR112021004734A2/en unknown
- 2019-09-13 CA CA3112401A patent/CA3112401A1/en active Pending
- 2019-09-13 WO PCT/EP2019/074511 patent/WO2020053398A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021004734A2 (en) | 2021-06-08 |
WO2020053398A2 (en) | 2020-03-19 |
AU2019338666A1 (en) | 2021-04-08 |
EP3850363A2 (en) | 2021-07-21 |
PE20210746A1 (en) | 2021-04-20 |
US20200088726A1 (en) | 2020-03-19 |
CA3112401A1 (en) | 2020-03-19 |
TW202017940A (en) | 2020-05-16 |
WO2020053398A3 (en) | 2020-12-17 |
CR20210177A (en) | 2021-06-10 |
DE102018122546B3 (en) | 2019-12-05 |
KR20210060530A (en) | 2021-05-26 |
CN113195529A (en) | 2021-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202101910QA (en) | Method for high throughput peptide-mhc affinity screening for tcr ligands by stabilised, peptide-free mhc complexes | |
IL273217A (en) | Novel bispecific polypeptide complexes | |
IL263083A (en) | Single chain variable fragment cd3 binding proteins | |
SG11202012181PA (en) | Technologies for file sharing | |
MX2017012805A (en) | Antigen binding complex having agonistic activity and methods of use. | |
EP3408671C0 (en) | Methods for assaying t-cell dependent bispecific antibodies | |
GB201711655D0 (en) | Method for quickly screening diamonds for batches | |
SG11202004939SA (en) | Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody | |
IL281570A (en) | Methods for purifying heterodimeric, multispecific antibodies | |
ZA202004627B (en) | Colour grading process and system for diamonds | |
GB2578016B (en) | Material mesh for screening fines | |
SG11202007688YA (en) | Toll-like receptor ligands | |
IL280884A (en) | Methods for characterizing protein complexes | |
IL281476A (en) | Method for high throughput peptide-mhc affinity screening for tcr ligands by stabilised, peptide-free mhc complexes | |
EP3645166A4 (en) | Apparatuses for reaction screening and optimization, and methods thereof | |
EP3567047A4 (en) | Chemical method for preparing heme iron not derived from porcine blood | |
GB2587264B (en) | Method for preparing miscible nanosuspension | |
IL264490A (en) | High throughput cell-based screening for aptamers | |
ZA201704218B (en) | Support for tensioned screening media | |
GB2580513B (en) | Method for preparing modified molecular sieve | |
ZA202000196B (en) | Processes for purifying ligands | |
GB201816403D0 (en) | Apparatus for high density, automated culivation | |
GB201806004D0 (en) | Selective ligands for TAU aggregates | |
WO2017075045A3 (en) | Antibodies to b7-h1 | |
WO2016018939A3 (en) | Methods for separating mixtures |